News of Note—Gritstone’s EVP, Trump’s opioid vaccine plan and more

non
In this week's news of note, Gritstone Oncology hired an industry veteran as its technical operations head. (Pixabay)

Here's some other vaccine news of note for the week.

> Cancer vaccine startup Gritstone Oncology hired Jayant Aphale, Ph.D., as EVP of technical operations. He previously served senior roles at Sarepta, GlaxoSmithKline Vaccines, Acambis and Wyeth Vaccines. Release

> President Donald Trump unveiled a new plan to combat the opioid crisis, including support for research into developing a vaccine for opioid addiction. CNBC article

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

> The Philippine government will seek congressional permission to use refunds for unused Dengvaxia shots from Sanofi to support related medical needs of those already inoculated. ABS-CBN article

> TapImmune’s shares rose 17% premarket Thursday after the company said its TPIV200 T-cell vaccine did well in a phase 1 study in patients with ovarian and breast cancer. MarketWatch article